Ibrance/fulvestrant (palbociclib/fulvestrant)

pCPA File Number: 21134
Negotiation Status:
Concluded with an LOI
Indication(s):
Advanced or Metastatic Breast Cancer
Sponsor/Manufacturer:
Pfizer Canada ULC
CDA-AMC Project Number:
PC0150-000
pCPA Engagement Letter Issued:
Negotiation Process Concluded: